EUVIMEDEUVIMED entdecken
Crossref

Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy

Xuanbo Zhang, Kaiyuan Wang iD, Zhiqiang Zhao, Xinzhu Shan, Yuequan Wang, Zunyong Feng, Bingyu Li, Cong Luo iD, Xiaoyuan Chen iD, Jin Sun iD

ACS Nano · 2024

DOI: 10.1021/acsnano.3c11637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2024. Verfasst von Xuanbo Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, P. R. China. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms, Nanoparticles. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Ministry of Education - Singapore, National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tapping into the innate immune system's power, nanovaccines can induce tumor-specific immune responses, which is a promising strategy in cancer immunotherapy. However, traditional vaccine design, requiring simultaneous loading of antigens and adjuvants, is complex and poses challenges for mass production. Here, we developed a tumor nanovaccine platform that integrates adjuvant functions into the delivery vehicle, using branched polyguanidine (PolyGu) nanovaccines. These nanovaccines were produced by modifying polyethylenimine (PEI) with various guanidine groups, transforming PEI's cytotoxicity into innate immune activation. The PolyGu nanovaccines based on poly(phenyl biguanidine ) (Poly-PBG) effectively stimulated dendritic cells, promoted their maturation via the TLR4 and NLRP3 pathways, and displayed robust in vivo immune activity. They significantly inhibited tumor growth and extended mouse survival. The PolyGu also showed promise for constructing more potent mRNA-based nanovaccines, offering a platform for personalized cancer vaccine. This work advances cancer immunotherapy toward potential clinical application by introducing a paradigm for developing self-adjuvanting nanovaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesNeoplasmsNanoparticlesAnimalsMiceNanovaccinesAdjuvants, ImmunologicImmunotherapy

Stichwörter der Autor:innen

adjuvantscancer immunotherapyguanidiniummRNAnanovaccines

Substanzen

NanovaccinesAdjuvants, ImmunologicCancer Vaccines

Autor:innen und Institutionen

  • Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, P. R. China.
  • Departments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, S…
  • Joint International Research Laboratory of Intelligent Drug Delivery Systems of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
  • Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.
  • Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
  • Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Singapore.

ORCID-Profile: Kaiyuan Wang, Cong Luo, Xiaoyuan Chen, Jin Sun

Förderung

  • National Key Research and Development Program of China
  • Ministry of Education - Singapore
  • National Medical Research Council
  • National Research Foundation Singapore
  • National University of Singapore

Zitieren

APA

Zhang, X., Wang, K., Zhao, Z., Shan, X., Wang, Y., Feng, Z., Li, B., Luo, C., Chen, X., & Sun, J. (2024). Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy. ACS Nano. https://doi.org/10.1021/acsnano.3c11637

Vancouver

Zhang X, Wang K, Zhao Z, Shan X, Wang Y, Feng Z, et al. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy. ACS Nano. 2024. doi:10.1021/acsnano.3c11637

BibTeX
@article{Zhang2024,
  author = {Zhang, Xuanbo and Wang, Kaiyuan and Zhao, Zhiqiang and Shan, Xinzhu and Wang, Yuequan and Feng, Zunyong and Li, Bingyu and Luo, Cong and Chen, Xiaoyuan and Sun, Jin},
  title = {Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy},
  journal = {ACS Nano},
  year = {2024},
  doi = {10.1021/acsnano.3c11637}
}
Kostenlos starten →